Steris price target raised to $265 from $260 at Piper Sandler

Piper Sandler raised the firm’s price target on Steris (STE) to $265 from $260 and keeps an Overweight rating on the shares. The firm sees the quarter as solid for Steris’ HC franchise, and believes AST could also post better performance on a comp-adjusted basis.